Prognostic impact of pretreatment thrombocytosis in epithelial ovarian cancer.
Prognostic impact of pretreatment thrombocytosis in epithelial ovarian cancer.
复制标题
DOI：
10.4103/njcp.njcp_134_19
复制
发表时间：
2020-08
影响因子：
0.9
通讯作者：
Anorlu RI
中科院分区：
文献类型：
--
作者：
Okunade KS;Dawodu O;Adenekan M;Nwogu CM;Awofeso O;Ugwu AO;Salako O;John-Olabode S;Olowoselu OF;Anorlu RI
本研究旨在调查尼日利亚拉各斯的上皮性卵巢癌（EOC）患者治疗前血小板增多对预后的影响。这是一项回顾性队列研究，涉及审查2010年1月至2016年12月7年期间在尼日利亚拉各斯的拉各斯大学教学医院接受治疗的72例经组织学证实的EOC患者的临床记录。从患者病历中检索EOC诊断时的社会人口学数据和血小板计数信息。然后计算所有基线患者特征的描述性统计量。使用Kaplan-Meier估计值进行生存分析。采用考克斯比例风险模型对这些数据进行多变量分析。本研究显示卵巢上皮性癌患者治疗前血小板增多的患病率为41.7%。53名（73.6%）女性患有晚期疾病（FIGO III-IV期），而52名（72.2%）患有高级别疾病（II-III期）。大多数（66.7%）的妇女有浆液性组织学类型的EOC，而76.4%的记录复发。治疗前血小板增多症与妇女的产次显著相关（P = 0.009），血清碳水化合物抗原125水平（P = 0.018），中位无进展生存期（PFS）（P < 0.001），3年中位总生存期（OS）（P < 0.001），主要治疗类型（P = 0.002），细胞减少程度有无腹水（P = 0.002）、国际妇产科联合会（FIGO）分期（P = 0.008）和组织学类型（P = 0.011）。治疗前血小板增多与PFS（风险比[HR] = 0.25; 95% CI 0.83，0.75; P = 0.014）和3年OS（HR = 0.03; 95% CI 0.03，0.27; P = 0.002）呈负相关。该研究表明，治疗前血小板增多可能是EOC患者生存的一个有用的预测因子。
This study was aimed at investigating the prognostic impact of pretreatment thrombocytosis in epithelial ovarian cancer (EOC) patients in Lagos, Nigeria. This was a retrospective cohort study involving the review of the clinical record of 72 patients with histologically confirmed EOC who were managed at the Lagos University Teaching Hospital, Lagos, Nigeria over a 7-year period from January 2010 to December 2016. Information on the sociodemographic data and platelet counts at diagnosis of EOC were retrieved from the patients’ medical records. Descriptive statistics were then computed for all baseline patients’ characteristics. Survival analyses were carried out using the Kaplan-Meier estimates. Multivariate analysis of these data was performed with the Cox proportional hazards model. This study revealed that the prevalence of pretreatment thrombocytosis was 41.7% among the women with EOC. Fifty-three (73.6%) of the women had the advanced-stage disease (FIGO stage III-IV) while 52 (72.2%) had high-grade disease (II-III). The majority (66.7%) of the women had a serous histological type of EOC while 76.4% had documented recurrence. Pretreatment thrombocytosis was significantly associated with the women’s parity (P = 0.009), serum carbohydrate antigen 125 levels (P = 0.018), median progression-free survival (PFS) (P < 0.001), 3-year median overall survival (OS) (P < 0.001), type of primary treatment (P = 0.002), extent of cytoreduction (P < 0.001), presence of ascites (P = 0.002), International Federation of Gynecology and Obstetrics (FIGO) stage (P = 0.008), and histological type (P = 0.011). Pretreatment thrombocytosis was negatively associated with PFS (hazard ratio [HR] = 0.25; 95% CI 0.83, 0.75; P = 0.014) and 3-year OS (HR = 0.03; 95% CI 0.03, 0.27; P = 0.002). The study suggests that pretreatment thrombocytosis may be a useful predictor of survivals in EOC patients.
登录
查看更多内容
影响因子：
--
作者：
LEVIN, J;CONLEY, CL
通讯作者：
CONLEY, CL
影响因子：
4.7
作者：
Allensworth SK;Langstraat CL;Martin JR;Lemens MA;McGree ME;Weaver AL;Dowdy SC;Podratz KC;Bakkum-Gamez JN
通讯作者：
Bakkum-Gamez JN
影响因子：
2.3
作者：
Wei SU;Li H;Zhang B
通讯作者：
Zhang B
影响因子：
4.4
作者：
Ogata, Yuko;Hepplmann, Carrie J.;Muddiman, David C.
通讯作者：
Muddiman, David C.
DOI：
10.1038/nrc3004
发表时间：
2011-03
期刊：
Nature reviews. Cancer
影响因子：
--
作者：
Gay LJ;Felding-Habermann B
通讯作者：
Felding-Habermann B